| Revision as of 19:56, 28 December 2024 editAnomieBOT (talk | contribs)Bots6,567,057 editsm Dating maintenance tags: {{One source}}← Previous edit | Latest revision as of 01:09, 29 December 2024 edit undoGoingBatty (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, Pending changes reviewers, Rollbackers639,574 edits added Category:Bladder cancer; removed {{uncategorized}} using HotCat | ||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| {{One source|date=December 2024}} | |||
| {{Short description|Laboratory test for bladder cancer}} | {{Short description|Laboratory test for bladder cancer}} | ||
| The '''bladder tumour antigen''' (BTA) test is used in the detection of ]. It works by detecting raised levels of complement factor H‐related protein (CFHrp), which is produced by cancer cells, in urine. The test can be qualitative, in which just the presence of the antigen is detected or quantitative, in which the ''amount'' of the antigen is measured. |
The '''bladder tumour antigen''' (BTA) test is used in the detection of ]. It works by detecting raised levels of complement factor H‐related protein (CFHrp), which is produced by cancer cells, in urine. The test can be qualitative, in which just the presence of the antigen is detected or quantitative, in which the ''amount'' of the antigen is measured.<ref name="pmid35950042">{{cite journal |vauthors=Soputro NA, Gracias DN, Dias BH, Nzenza T, O'Connell H, Sethi K |title=Utility of urinary biomarkers in primary haematuria: Systematic review and meta-analysis |journal=BJUI Compass |volume=3 |issue=5 |pages=334–343 |date=September 2022 |pmid=35950042 |pmc=9349596 |doi=10.1002/bco2.147 |url=}}</ref><ref name="pmid24940462">{{cite journal |vauthors=Guo A, Wang X, Gao L, Shi J, Sun C, Wan Z |title=Bladder tumour antigen (BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer: A meta-analysis |journal=Canadian Urological Association Journal = Journal De l'Association Des Urologues Du Canada |volume=8 |issue=5-6 |pages=E347–52 |date=May 2014 |pmid=24940462 |pmc=4039599 |doi=10.5489/cuaj.1668 |url=}}</ref> | ||
| ==References== | ==References== | ||
| {{reflist}} | {{reflist}} | ||
| ] | |||
Latest revision as of 01:09, 29 December 2024
Laboratory test for bladder cancerThe bladder tumour antigen (BTA) test is used in the detection of bladder cancer. It works by detecting raised levels of complement factor H‐related protein (CFHrp), which is produced by cancer cells, in urine. The test can be qualitative, in which just the presence of the antigen is detected or quantitative, in which the amount of the antigen is measured.
References
- Soputro NA, Gracias DN, Dias BH, Nzenza T, O'Connell H, Sethi K (September 2022). "Utility of urinary biomarkers in primary haematuria: Systematic review and meta-analysis". BJUI Compass. 3 (5): 334–343. doi:10.1002/bco2.147. PMC 9349596. PMID 35950042.
- Guo A, Wang X, Gao L, Shi J, Sun C, Wan Z (May 2014). "Bladder tumour antigen (BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer: A meta-analysis". Canadian Urological Association Journal = Journal De l'Association Des Urologues Du Canada. 8 (5–6): E347–52. doi:10.5489/cuaj.1668. PMC 4039599. PMID 24940462.